首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1419141

前列腺癌治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按治療類型、最終用戶和地理位置

Prostate Cancer Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End User, and Geography

出版日期: 2023年12月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

攝護腺癌治療市場預計將從2022年的147.67億美元成長到2030年的284.25億美元；預計2022年至2030年CAGR為8.5%。

前列腺癌是男性最常見的健康問題之一，尤其是老年男性（50歲以上）。前列腺癌最常見於肥胖且有前列腺癌家族史的男性。前列腺癌是一種無聲的威脅，經常前列腺癌的發展沒有明顯的症狀，因此早期發現這種癌症並不容易。通常，大多數前列腺癌起源於前列腺的周圍區域。因此，為了使症狀變得明顯，癌症的大小必須達到它會對尿道造成壓力，或者在某些情況下，轉移引起的骨痛可能是晚期前列腺癌的首發症狀。但是，任何年齡在50 歲或以上、出現下泌尿道症狀、勃起功能障礙或血尿的個體考慮前列腺癌的可能性。前列腺癌是全球男性癌症死亡的第五大原因，也是第二常見的癌症。

強大的產品線為前列腺癌治療市場的成長創造機會

目前前列腺癌治療的前景廣闊，擁有多種藥物批准、豐富的產品線以及許多正在進行的臨床試驗。多種前列腺癌療法正處於臨床開發的不同階段；製藥巨頭正在努力擴大其產品線，這是前列腺癌治療市場的重大機會。以下提到了一些處於不同臨床研究階段的前列腺癌療法：

序號製造商產品名稱臨床試驗階段

1 阿斯利康 capivasertib 臨床 II 期

capivasertib + 阿比特龍 CAPtello-281 臨床 III 期

2 輝瑞PF-07220060+恩雜魯胺臨床I期

PF-06821497 + 恩雜魯胺臨床II期

TALZENNA 臨床 III 期

3 禮來Abemaciclib臨床III期

資料來源：ClinicalTrials.gov

使用化療、標靶治療和聯合治療治療前列腺癌的強大產品線預計很快就會推動前列腺癌治療市場的成長。

前列腺癌治療市場根據治療類型、最終用戶和地理位置進行分類。前列腺癌治療市場依治療類型分為荷爾蒙治療、化療、免疫治療、標靶治療等。依最終用戶分類，前列腺癌治療市場分為醫院、專科診所等。

根據地理位置，前列腺癌治療市場分為北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙、俄羅斯和歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳大利亞、東南亞和亞太地區其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲其他地區）。由於技術不斷進步、前列腺癌病例數量不斷增加、政府對不斷成長的產品線的支持以及主要市場參與者致力於新產品和現有產品的開發，2022年北美在全球前列腺癌治療市場中佔據最大佔有率。然而，預計2022年至2030年亞太地區的CAGR最高。2022年，美國在北美前列腺癌治療市場中佔據最大佔有率。美國前列腺癌治療市場的成長主要由發病率上升推動前列腺癌病例、產品發布和政府措施。公司推出的各種治療前列腺癌的產品也促進了市場成長。例如，2023年6月，阿斯特捷利康和默沙東的Lynparza（olaparib）合併潑尼鬆或潑尼松龍和阿比特龍在美國被批准用於治療疑似有害BRCA突變（BRCAm）轉移性去勢抵抗性前列腺癌（mCRPC）的成年患者）。此外，2023年11月，FDA批准了安斯泰來製藥美國公司生產的恩雜魯胺，用於治療生化復發且轉移風險高的非轉移性去勢敏感型前列腺癌（nmCSPC）。高風險BCR ）。除了皮膚癌之外，攝護腺癌是美國男性最常見的癌症之一。根據美國癌症協會估計，2023年將有約288,000例新發前列腺癌病例，預計約有34,700人死於攝護腺癌。根據同一來源，大約八分之一的男性在一生中會被診斷出患有前列腺癌。美國前列腺癌盛行率的不斷上升以及人們對前列腺癌早期檢測和早期治療的認知不斷增強，正在推動前列腺癌治療市場的成長。

ClinicalTrails.com、疾病管制與預防中心 (CDC)、食品藥物管理局 (FDA) 和國際標準化組織 (ISO) 是在準備前列腺癌治療市場報告時參考的幾個關鍵的主要和次要來源。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 10 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 11 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 12 章：前列腺癌治療市場 - 主要公司概況

Johnson and Johnson Services, Inc.

注意 - 將為以下公司列表提供類似資訊

拜耳公司
阿斯利康
安斯泰來製藥公司
禮來公司
賽諾菲
艾伯維公司
默克公司
諾華公司
百時美施貴寶

第 13 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00003423

The prostate cancer therapeutics market is expected to grow from US$ 14.767 billion in 2022 to US$ 28.425 billion by 2030; it is anticipated to record a CAGR of 8.5% from 2022 to 2030.

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years. Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Prostate cancer is the 5th leading cause of cancer death among men worldwide and the 2nd most commonly diagnosed cancer.

Strong Product Pipeline Creates Opportunity for the Growth of the Prostate Cancer Therapeutics Market

The current landscape for prostate cancer therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Multiple prostate cancer therapies are in various stages of clinical development; pharmaceutical giants are working to expand their pipeline, which is a major opportunity prevailing in the prostate cancer therapy market. A few of the prostate cancer therapies that are in different phases of clinical studies are mentioned below:

Sr. No. Manufacturer Product Name Clinical Trial Phase

1 AstraZeneca capivasertib Clinical Phase II

capivasertib + abiraterone CAPItello-281 Clinical Phase III

2 Pfizer PF-07220060 + enzalutamide Clinical Phase I

PF-06821497 + enzalutamide Clinical Phase II

TALZENNA Clinical Phase III

3 Lilly Abemaciclib Clinical Phase III

Source: ClinicalTrials.gov

A strong product pipeline for the treatment of prostate cancer using chemotherapy, targeted therapy, and combinational therapy is expected to fuel the growth of the prostate cancer therapeutics market shortly.

The prostate cancer therapeutics market is divided based on therapy type, end user, and geography. The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others.

Based on geography, the prostate cancer therapeutics market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global prostate cancer therapeutics market in 2022 owing to the increasing technological advancements, increasing number of prostate cancer cases, government support for the growing product pipeline, and major market players engaged in new and existing product developments. However, Asia Pacific is anticipated to register the highest CAGR from 2022 to 2030. The US held the largest share of North America's prostate cancer therapeutics market in 2022. The growth of the prostate cancer therapeutics market in the US is mainly driven by the increasing incidence of prostate cancer cases, product launches, and government initiatives. Various product launches by companies to treat prostate cancer also bolstered market growth. For instance, in June 2023, AstraZeneca and MSD's Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US for the treatment of adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). In addition, in November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc., which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). Other than skin cancer, prostate cancer is one of the most common cancers diagnosed in American men. According to the American Cancer Society Inc., it is estimated that in 2023, ~288,000 new cases of prostate cancer will be registered, and about 34,700 people are expected to die due to prostate cancer. As per the same source, ~ 1 in 8 men will be diagnosed with prostate cancer during their lifetime. This increasing prevalence of prostate cancer in the US and growing awareness about early detection and early treatment of prostate cancer in the US is fueling the growth of the prostate cancer therapeutics market.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and International Organization for Standardization (ISO) are a few key primary and secondary sources referred to while preparing the report on the prostate cancer therapeutics market.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Prostate Cancer Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Prostate Cancer Therapeutics Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Prostate Cancer Therapeutics Market - Global Market Analysis

6.1 Prostate Cancer Therapeutics - Global Market Overview
6.2 Prostate Cancer Therapeutics - Global Market and Forecast to 2030

7. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Therapy, 2020-2030

7.1 Overview
7.2 Hormonal Therapy
7.3 Chemotherapy
7.4 Targeted Therapy
7.5 Immunotherapy
7.6 Others

8. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

8.1 Overview
8.2 Hospitals
8.3 Specialty Clinics
8.4 Others

9. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

9.1 North America
- 9.1.1 North America Prostate Cancer Therapeutics Market Overview
- 9.1.2 North America Prostate Cancer Therapeutics Market Revenue and Forecasts to 2030
- 9.1.3 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Therapy
- 9.1.4 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
- 9.1.5 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Prostate Cancer Therapeutics Market
    - 9.1.5.1.1 United States Prostate Cancer Therapeutics Market, by Therapy
    - 9.1.5.1.2 United States Prostate Cancer Therapeutics Market, by Distribution Channel
  - 9.1.5.2 Canada Prostate Cancer Therapeutics Market
    - 9.1.5.2.1 Canada Prostate Cancer Therapeutics Market, by Therapy
    - 9.1.5.2.2 Canada Prostate Cancer Therapeutics Market, by Distribution Channel
  - 9.1.5.3 Mexico Prostate Cancer Therapeutics Market
    - 9.1.5.3.1 Mexico Prostate Cancer Therapeutics Market, by Therapy
    - 9.1.5.3.2 Mexico Prostate Cancer Therapeutics Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
- 9.4.4 Rest of Middle East and Africa
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Prostate Cancer Therapeutics Market - Key Company Profiles

12.1 Johnson and Johnson Services, Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies